Biological Profile of HIV-Positive Patients in Bangui, Central African Republic, in 2017
- 1 Institut Pasteur of Bangui, Medical Analysis Laboratory, Bangui, Central African Republic
- 2 Institut Pasteur of Bangui, Medical Analysis Laboratory, Bangui, Central African Republic
- 3 Institut Pasteur of Bangui, Epidemiology Service, Bangui, Central African Republic
- 4 Institut Pasteur of Bangui, Epidemiology Service, Bangui, Central African Republic
- 5 Institut Pasteur of Bangui, Medical Analysis Laboratory, Bangui, Central African Republic
- 6 Institut Pasteur of Bangui, Medical Analysis Laboratory, Bangui, Central African Republic
- 7 Institut Pasteur of Bangui, Medical Analysis Laboratory, Bangui, Central African Republic
- 8 Institut Pasteur of Bangui, Medical Analysis Laboratory, Bangui, Central African Republic
- 9 Institut Pasteur of Bangui, Medical Analysis Laboratory, Bangui, Central African Republic
- 10 Institut Pasteur of Bangui, Medical Analysis Laboratory, Bangui, Central African Republic
- 11 Institut Pasteur of Bangui, Medical Analysis Laboratory, Bangui, Central African Republic
- 12 Institut Pasteur of Bangui, Medical Analysis Laboratory, Bangui, Central African Republic
Abstract
Background : The biological profile of HIV-positive patients is essential for diagnosing treatment failure and the prognosis of infection. We determined the virological and immunological profiles and biological anomalies of HIV-positive people on antiretroviral therapy (ART) in Bangui, Central Afri-can Republic. Methods : We conducted an analytical, descriptive study be-tween 4 April and 30 September 2017 of all patients who had received ART for more than 12 months and who attended the Medical Analysis Laboratory of the Institut Pasteur in Bangui for a complete biological work-up, including viral load. A blood sample was taken for quantification of RNA HIV-1, CD4 lymphocytes and blood count in two tubes containing ethylenediamine te-traacetic acid, and another sample was taken in a dry tube for measurement of creatinine and transaminases. Results: The total population comprised 1748 patients, with a mean age of 38.7 years (±14.3; median, 41 years; range, 2 - 79 years); 33.3% of patients were between 40 and 49 years old. Females predo-minated (71.3%), for a sex ratio of 0.4. Immunological failure was observed in 20.2% of patients (CD4 < 200 cells/μL), and 44.5% of patients had a load of RNA HIV-1 ≥ 1000 copies/mL. The main haematological anomalies were anaemia (28.0%), leukopenia (26.7%), neutropenia (42.1%) and lymphopenia (27.2%). Blood creatinine was abnormal in 61.0% of patients, ALAT in 57.0% and ASAT in 66.9%. Conclusion: The abnormalities observed in this study concerned the haematopoietic system, the liver and the kidneys. As other or-gans and systems may be affected, periodic multidisciplinary biological and clinical follow-up is necessary for people living with HIV in order to improve their management.
- UNAIDS (2017) Fact sheet World AIDS Day. UNAIDS, Geneva, 1-8. http://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf
- Centers for Disease Control and Prevention. (1993) Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS among Adolescents and Adults. Morbidity and Mortality Weekly Report, 41, 1-19.
- Chêne, G., Binquet, C., Moreau, J.F., Neau, D., Pellegrin, L., Malvy, D., et al. (1998) Change in CD4+ Cell Count and the Risk of Opportunistic Infection or Death after Highly Active Antiretroviral Treatment. AIDS, 12, 2313-2320. https://doi.org/10.1097/00002030-199817000-00013
- Hammer, S.M., Squires, K.E., Hugues, M.D., Grimes, J.M., Demeter, L.M., Currier, J.S., et al. (1997) A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less. The New England Journal of Medicine, 337, 725-733. https://doi.org/10.1056/NEJM199709113371101
- Ba-Fall, K., Gueye, P.M., Lefevre, N., Fall, I.S., Said Ali Saindou, N., et al. (2004) Evolution of Antiretroviral Treatment of HIV/AIDS Infection at Dakar Main Hospital. Médecine Tropicale, 64, 292-293.
- Montagnier, L. (1998) AIDS and HIV Infection. Flammarion, Paris.
- Kobangue, L., Gody, J.C., Diemer, S.C.H., Biguene-Sapoua-Boka, Y., Dibere Kamba, G.D. and Bobossy Serengbe, G. (2016) Epidemiological, Clinical, Biological and Therapeutic Aspects of Children Dying on Antiretrovirals at the Bangui Pediatric Complex, Central African Republic. Revue de CAMES Science de Santé, 4, 15-18.
- Beuzit, Y., Bougarel, J. and Ngouonimba, J. (1992) Peripheral and Medullary Hematologic Changes in HIV Infection in Central Africa. Médecine Tropicale, 52, 193-199.
- Aceti, A., Pasquazzi, C., Zechini, B., De Bac, C., Liverhaart Group. (2002) Hepatotoxicity Development during Antiretroviral Therapy Containing Protease Inhibitors in Patients with HIV. The Role of Hepatitis B and C Virus Infection. Journal of AIDS, 29, 41-48. https://doi.org/10.1097/00042560-200201010-00005
- Carr, A. and Cooper, D.A. (2000) Adverse Effects of Antiretroviral Therapy. Lancet, 356, 1423-1430. https://doi.org/10.1016/S0140-6736(00)02854-3
- Malaty, L. and Kuper, J. (1999) Drug Interactions of HIV Protease Inhibitors. Drug Safety, 20, 147-169. https://doi.org/10.2165/00002018-199920020-00005